Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes.
Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes.
复制标题
前列腺素 E2 和 F2 α 对猫和恒河猴眼睛的降血压和其他眼部作用的比较。
DOI：
--
复制
发表时间：
1982
影响因子：
4.4
通讯作者：
L. Bito
中科院分区：
文献类型：
--
作者：
F. Stern;L. Bito
人们普遍认为外源性或内源性前列腺素（pg）可引起眼压（IOP）的急性升高，并引起光斑和其他葡萄膜炎的症状。然而，最近的研究表明，小剂量的PGE2和/或PGF2 α局部应用于兔或猫头鹰猴的眼睛可显著降低IOP。目前的实验表明，局部应用10至500微克的PGE2也会导致猫眼的IOP显著降低，持续时间长达48小时，很少或没有发生耀斑或瞳孔缩小，而类似的PGF2 α应用除了会导致IOP降低外，还会导致瞳孔严重收缩。PGF2 α或PGE2局部应用于恒河猴的眼睛也会导致IOP显著的剂量依赖性降低。恒河猴的降压反应与可检测到的闪光或持续的瞳孔收缩无关，尽管在较高的PG剂量下，两种动物的降压往往先出现短暂的（15至30分钟）高血压期。结果表明，不同物种的眼睛对局部应用的PGs表现出不同的IOP，瞳孔和耀斑反应模式，唯一一致的效果是IOP降低。在某些物种中，尤其是灵长类动物，眼压降低是pg的主要作用。因此，PGs或其类似物可能为临床控制眼压和治疗青光眼提供新的途径。
It is generally accepted that exogenous or endogenous prostaglandins (PGs) can give rise to acute increases in intraocular pressure (IOP) and to the development of flare and other signs of uveitis. It was recently shown, however, that low doses of PGE2 and/or PGF2 alpha topically applied to rabbit or owl monkey eyes significantly reduce IOP. The present experiments show that topical application of 10 to 500 micrograms of PGE2 also causes a highly significant IOP reduction in cat eyes lasting up to 48 hr with little or no development of flare or miosis, whereas similar application of PGF2 alpha causes, in addition to an IOP reduction, the development of profound pupillary constriction. Topical application of either PGF2 alpha or PGE2 to the eyes of rhesus monkeys also causes significant dose-dependent reduction in IOP. The hypotensive response in the rhesus monkey is not associated with detectable flare or consistent pupillary constriction, although at higher PG doses, hypotension tends to be preceded in both species by a brief (15 to 30 min) hypertensive phase. It is concluded that the eyes of different species show different patterns of IOP, miotic, and flare responses to topically applied PGs, the only consistent effect being a reduction in IOP. In some species, most notably in primates, a reduction in IOP is the predominant effect of PGs. Thus, PGs or their analogues may provide a new approach to the clinical control of IOP and the treatment of glaucoma.